Details of Drug-Drug Interaction
| Drug General Information (ID: DDIAFQ76ZJ) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Tubocurarine | Drug Info | Lincomycin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Neuromuscular Blocking Agents | Antibiotics | |||||||
| Structure | |||||||||
| Mechanism of Tubocurarine-Lincomycin Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive neuromuscular blocking effects Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Tubocurarine | Lincomycin | |||||||
| Mechanism |
Neuromuscular blocking agent Neuronal acetylcholine receptor Antagonist |
Neuromuscular blocking effects Lincosamides |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Neuronal acetylcholine receptor | Structure Sequence | |||||||
| Protein Family | Ligand-gated ion channel (TC 1.A.9) family | ||||||||
| Protein Function |
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Patients receiving neuromuscular blockers in conjunction with lincosamide therapy should be monitored closely during and after anesthesia for development of respiratory depression, and life support should be readily available if needed. Anticholinesterases and calcium may not completely antagonize the neuromuscular blockade induced by lincosamides. | ||||||||

